EFFECT OF SILIBININ ON BILIARY LIPID-COMPOSITION - EXPERIMENTAL AND CLINICAL-STUDY

被引:38
|
作者
NASSUATO, G
IEMMOLO, RM
STRAZZABOSCO, M
LIRUSSI, F
DEANA, R
FRANCESCONI, MA
MURACA, M
PASSERA, D
FRAGASSO, A
ORLANDO, R
CSOMOS, G
OKOLICSANYI, L
机构
[1] MADAUS AG,COLOGNE,GERMANY
[2] UNIV PARMA,IST CLIN MED & NEFROL,I-43100 PARMA,ITALY
[3] UNIV PADUA,IST MED INTERNA,I-35100 PADUA,ITALY
[4] UNIV PADUA,DIPARTMENTO CHIM BIOL,I-35100 PADUA,ITALY
关键词
D O I
10.1016/0168-8278(91)90829-Z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The effect of Silymarin, a natural flavonoid, on biliary lipid composition, was studied in rats and humans. Bile flow, biliary cholesterol, phospholipid and total bile salt concentrations were measured in 23 control rats and in 27 rats treated with Silibinin, the active component of Silymarin, at the dose of 100 mg/kg body weight i.p. (n = 21) or 50 mg/kg body weight i.p. (n = 6) for 7 days. Biliary cholesterol and phospholipid concentrations were significantly reduced after the higher Silibinin dose (60.9 and 72.9% of the control values), whereas bile flow and biliary total bile salt concentration were unchanged. After the lower Silibinin dose all parameters remained unchanged. Total liver cholesterol content was not affected by Silibinin. On the other hand, in vitro determination of rat liver microsomal 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase activity showed a significant dose-dependent inhibition by Silibinin (0.5-8 mg/kg). Biliary lipid composition was also assayed in four gallstone and in 15 cholecystectomized patients before and after Silymarin (420 mg per day for 30 days) or placebo administration. In both groups, biliary cholesterol concentrations were reduced after Silymarin treatment and the bile saturation index significantly decreased accordingly. These data suggest that Silibinin-induced reduction of biliary cholesterol concentration both in humans and in rats might be, at least in part, due to a decreased synthesis of liver cholesterol.
引用
收藏
页码:290 / 295
页数:6
相关论文
共 50 条
  • [1] EFFECT OF SILYBIN ON BILIARY LIPID-COMPOSITION
    NASSUATO, G
    IEMMOLO, RM
    ORLANDO, R
    STRAZZABOSCO, M
    MURACA, M
    CSOMOS, G
    OFFOLICSANYI, L
    ITALIAN JOURNAL OF GASTROENTEROLOGY, 1984, 16 (03): : 277 - 278
  • [2] EFFECT OF LACTULOSE ON BILIARY LIPID-COMPOSITION
    HENEGOUWEN, GPV
    VANDERWERF, SDJ
    RUBEN, AT
    JOURNAL OF HEPATOLOGY, 1986, 3 (03) : 328 - 332
  • [3] THE EFFECT OF HIBERNATION ON BILIARY LIPID-COMPOSITION
    SHAFFER, EA
    FRIDHANDLER, T
    CLINICAL RESEARCH, 1983, 31 (01): : A34 - A34
  • [4] EFFECT OF SILYBIN ON BILIARY LIPID-COMPOSITION IN RATS
    NASSUATO, G
    IEMMOLO, RM
    LIRUSSI, F
    ORLANDO, R
    GIACON, L
    VENUTI, M
    STRAZZABOSCO, M
    CSOMOS, G
    OKOLICSANYI, L
    PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1983, 15 (04): : 337 - 346
  • [5] THE EFFECT OF LIPID INFUSION ON LIVER AND BILIARY LIPID-COMPOSITION IN RATS
    HALPERN, Z
    RUBIN, M
    DEVIR, A
    GILAT, T
    LICHTENBERG, D
    WENNBERG, A
    HEPATOLOGY, 1991, 14 (04) : A252 - A252
  • [6] AGING AND BILIARY LIPID-COMPOSITION
    PONZDELEON, M
    CARULLI, N
    GIORNALE DI GERONTOLOGIA, 1978, 26 (12) : 921 - 922
  • [7] BILIARY LIPID-COMPOSITION IN HYPERLIPOPROTEINEMIA
    AHLBERG, J
    ANGELIN, B
    EINARSSON, K
    HELLSTROM, K
    LEIJD, B
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1980, 15 (02) : 11 - 11
  • [8] BILIARY LIPID-COMPOSITION IN OBESITY
    ANGELIN, B
    EINARSSON, K
    EWERTH, S
    LEIJD, B
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1981, 16 (08) : 1015 - 1019
  • [9] EFFECT OF URSODEOXYCHOLIC ACID ON BILIARY LIPID-COMPOSITION - A DOUBLE-BLIND-STUDY
    ATTILI, AF
    ANGELICO, M
    CAPOCACCIA, P
    GUALDI, G
    CANTAFORA, A
    DIBIASE, A
    CAPOCACCIA, L
    GIUNCHI, G
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1980, 12 (03): : 177 - 180
  • [10] EFFECT OF TAUROURSODEOXYCHOLIC ACID ON BILIARY LIPID-COMPOSITION - A DOSE-RESPONSE STUDY
    MURACA, M
    VILEI, MT
    CIANCI, V
    LIU, XT
    GAROTTA, F
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1995, 33 (07) : 391 - 393